What Anumana Announced About Its Cardiac Amyloidosis ECG Clearance

Anumana said on 8 April 2026 that the FDA cleared its ECG-AI algorithm for cardiac amyloidosis read from a standard 12-lead ECG, and the company calls it the first and only one cleared for that use on a standard 12-lead test. Anumana reports 78.9 percent sensitivity and 91.2 percent specificity in adults, from company data on file covering 25,525 patients at four United States health systems. The company also says the device had earlier received FDA Breakthrough Device Designation.

Why the Anumana Cardiac Amyloidosis Clearance Matters to Hospital Buyers

Hospitals already record ECGs by the million, so a cleared algorithm that reads an existing test costs less to add than a new scanner. The performance figures are the company's own data on file rather than an independent trial, and a sensitivity of 78.9 percent means roughly one in five people with the condition in that study group was not flagged. Clearance means the FDA accepted the submission for this use. It does not show how the algorithm will behave on a different patient mix.

Where the Anumana Update Comes From

Anumana is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Anumana original source.

How We Would Research the Anumana Cardiac Amyloidosis Clearance

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would start with the 510(k) record itself and read the indications for use, so the cleared claim is clear before any sales material is read.
  2. Then we would ask Anumana for the published version of the 25,525-patient analysis, including how many of those patients came from each of the four health systems.
  3. We would compare the age mix and case mix in that analysis against our own ECG volume, because a rare condition behaves differently in a different population.